Ksenia Titorenko

Years Active: 2021-2023
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Nobuko Hijiya, Alexey A Maschan, Carmelo Rizzari, Hiroyuki Shimada, Carlo Dufour, Hiroaki Goto, Hyoung Jin Kang, Terri Guinipero, Zeynep Karakas, Francisco J Bautista Sirvent, Stéphane Ducassou, Keon Hee Yoo, Christian Michel Zwaan, Frédéric Millot, Briana Patterson, Jill H Samis, Miguel Izquierdo, Ksenia Titorenko, Sai Li, Darintr Sosothikul
The Long-term Efficacy and Safety of Nilotinib in Pediatric Patients With CML: a 5-Year Update of the DIALOG Study. Blood advances (2023)
Nobuko Hijiya, Alexey A Maschan, Carmelo Rizzari, Hiroyuki Shimada, Carlo Dufour, Hiroaki Goto, Hyoung Jin Kang, Terri Guinipero, Zeynep Karakas, Francisco Bautista, Stéphane Ducassou, Keon Hee Yoo, Christian Michel Zwaan, Frédéric Millot, Briana Patterson, Jill H Samis, Paola Aimone, Alex Allepuz, Ksenia Titorenko, Darintr Sosothikul
A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety. Blood advances 5 (14) (2021)
Jerald P Radich, Andreas Hochhaus, Tamas Masszi, Andrzej Hellmann, Jesper Stentoft, María Teresa Gómez Casares, J Valentín García-Gutiérrez, Eibhlin Conneally, Philipp D le Coutre, Norbert Gattermann, Bruno Martino, Susanne Saussele, Francis J Giles, David Morrall Ross, Paola Aimone, Sai Li, Ksenia Titorenko, Giuseppe Saglio
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia 35 (5) (2021)

Ksenia Titorenko.css-eqlu8i{font-size:small;padding-left:4px;}